Clinical Trial Update: Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors [Phase 3]

View source ↗

Summary

Pfizer is conducting an open-label extension of marstacimab in Hemophilia A or Hemophilia B patients, including those with or without inhibitors, as a Phase 3 s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Marstacimab (Marstacimab)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A, Hemophilia B | Phase 3 | Status: RECRUITING